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Background: Treatment of cardiac syndrome X with unknown pathological mechanism remains a big challenge for
clinicians. Complementary and alternative medicine may bring a new choice for its management. The aim of this
study is to evaluate the clinical effects of traditional Chinese medicine on cardiac syndrome X patients.
Methods: We systematically searched databases such as Cochrane CENTRAL, PubMed, EMBASE, CBM, Chinese
National Knowledge Infrastructure (CNKI), WanFang and VIP, and handsearched relevant journals to identify
randomized controlled trials. Following the steps of systematic review recommended by the Cochrane group, we
assessed the quality of included studies, extracted valid data and undertook meta-analysis.
Results: Twenty one moderate-to low-quality randomized controlled trials involving 1143 patients were included.
The results showed that traditional Chinese medicine could improve angina [OR=1.34, 95% CI: 1.2 to 1.50],
electrocardiogram (ECG), endothelin-1 (ET-1) levels, prolong exercise duration in treadmill tests, and reduce angina
frequency per week compared with routine treatment. No other side effect was reported except two cases of
stomach pain.
Conclusion: Compared with conventional treatment, traditional Chinese medicine shows the potential of
optimizing symptomatic outcomes and improving ECG and exercise duration. The efficacy of TCM may find
explanation in its pharmacological activity of adjusting the endothelial function. TCM, as a kind of alternative and
complementary medicine, may provide another choice for CSX patients.Background
Cardiac syndrome X (CSX, also called microvascular an-
gina) refers to typical stable angina that is exclusively or
predominantly induced by effort. Upon diagnostic investi-
gation, findings are comparable to those of myocardial is-
chemia, showing normal or near-normal coronary arteries
on angiography and an absence of any other specific car-
diac diseases (e.g., variant angina, cardiomyopathy, or
valvular diseases) [1]. Approximately 10% to 20% of af-
fected patients suspected to have angina reportedly turned
out to have negative coronary angiogram results [2]. Al-
though the long-term prognosis of CSX does not* Correspondence: shanghongcai@foxmail.com
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reproduction in any medium, provided the ornecessarily include increased mortality, patients’ quality of
life is invariably affected and the incidence rates of cardio-
vascular and cerebrovascular events are increased [3]. Ex-
acerbated and recurrent angina may also lead to physical
discomfort, frequent hospital readmissions, or even repeat
coronary angiography, imposing patients with a huge eco-
nomic burden [4]. Moreover, patients with CSX tend to
show high scores on psychological inventories that meas-
ure anxiety and depression [5].
The etiology and pathology of CSX remain unclear. Al-
though hypotheses claiming that the disease is associated
with endothelial dysfunction, inflammation, oxidative
stress, or estrogen deficiency have been formulated, they
lack evidence [6,7]. Internationally, conventional drugs
against ischemia, such as beta-blockers, calcium antago-
nists, xanthine derivatives, angiotensin-converting en-
zyme inhibitors, estrogen, and statins, are recommended
for clinical use in patients with CSX. However, theirtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 A flow diagram of study selection followed the PRISMA template.
Wang et al. BMC Complementary and Alternative Medicine 2013, 13:62 Page 2 of 12
http://www.biomedcentral.com/1472-6882/13/62respective curative effects remain controversial [8-10].
We believe that alternative and complementary medicine
may provide additional treatment options. As more pa-
pers on treatment with Traditional Chinese Medicine
(TCM) were published in recent years, it was suggested
that Chinese herbs might bring health benefits for
patients with CSX [3]. TCM has a unique system of
interpreting the etiology and pathology of CSX [11],
allowing this syndrome to be treated accordingly.Moreover, modern pharmacological studies have found
that the active ingredients in many of these herbs
have functions related to endothelial protection, anti-
inflammation, antioxidative stress, and improvement of
estrogen function, all of which are believed to be effective
in the pathology of CSX [12-17]. Therefore, the relatively
inexpensive TCM treatment for CSX is worthy of atten-
tion. This study aimed to systematically and objectively
evaluate the clinical curative effect and safety of TCM for
Table 1 General characteristic of the included studies
Studies Case Age Gender Co F CP Outcome AE CI Type of TI TI
Year* (T/C) (M/F) (d)
Sun 2007 [24] 64(34/30) 37~62 T:13/21C:11/19 56 0 y AF,TT U RT Chinese patent
drug
Shenwuguanxinning granules 15 g
tid + RT
Ge 2011 [25] 39(19/20) 45~56 10/29 28 0 y A,AF,TTET-1 U RT Decoction Nourishing Qi and Blood
Decoction 1 150 mL qd + RT
Peng 2011 [26] 46(23/23) 35~65 18/28 56 0 y A,AF,TT N RT Chinese patent
drug
Xinnaotong capsule 0.8 g bid + RT
Niu 2008 [27] 50(30/20) 35~65 21/29 28 0 y A,AF,ECG,TT,TCM N RT Chinese patent
drug
Xinxuean granules 15 g tid + RT
Gao 2005 [28] 63(33/30) 45~64 0/63 28 0 y A U RT Decoction Xiaoyao decoction2 150 mL bid
Xu 2011 [29] 30(15/15) 35~60 10/20 28 0 y A,AF,TT U RT Chinese patent
drug
Wenxin granules3 9 g, tid + RT
Bi 2003 [30] 60(30/30) 44~61 27/33 28 6 m y A N RT Chinese patent
drug
Tongxinluo 1.52 g, tid
Wang 2009 [31] 55(28/27) 43~65 T: 5/23 C: 3/24 14 0 y A,ECG,TCM,TTET-1,
NOhs-CRP
N RT Decoction Kuanxionghuoxue decoction4
150 ml bid + RT
Xu LJ 2002 [32] 56(36/20) 31~48 T:23/13 C:13/7 7 7d y A,ET-1,Holter U RT Chinese patent
drug
Quanshi capsule 1.5 g tid
Liu 2008 [33] 58(38/20) 36~55 37/21 U 0 y A,ECG U RT Chinese patent
drug
Naoxintong tablets, 1.6 g, tid
Zhang 2002 [34] 40(20/20) 30~59 18/22 15 0 y A,ECG U RT Decoction Taohongsiwu decoction5 150 mL
qd
Lu 2007 [35] 114(72/72 18~60 56/88 84 0 y TT,ECG N RT Chinese patent
drug
Tongxinluo capsule 1.52 g tid
Zhu 2003 [36] 60(30/30) 30~59 38/22 15 0 y A,ECG U RT Decoction Xuefuzhuyu decoction 6150 mL qd
Liang 2005 [37] 42(21/21) 51~60 12/30 28 0 y A,AF, TCM,TT hs-
CRP
N RT placebo Chinese patent drug
Danshen tablets, three
tablets per time, tid +
RT
Yuan 2008 [38] 40(20/20) 48~67 T:9/11 C:13/7 28 0 y AF,TT U RT Injection Danhong injection 30 ml + 5%
glu or 0.9% NaCI 250 ml, iv, qd
Wang GF 2008 [39] 36(18/18) 33~70 T:3/15 C:2/16 28 0 y AF,TT,CRP,ET-1,NO N RT Decoction Guanmailing decoction7 150 ml
bid+ RT
Zhang SL 2008 [40] 72(36/36) 37~62 T:6/30 C:3/31 20 0 y A N R Chinese patent
drug
Guanmaining8 10 ml tid + xiaoyao
pill, 8 pills, tid+ RT
Zhang XY 2008 [41] 68(48/28) 42~58 T:11/37 C:6/14 21 0 y A,ECG U RT Decoction Individualized Chinese formulas
against different patterns of

























Table 1 General characteristic of the included studies (Continued)
Wu 2010 [42] 50(26/24) 39~50 T:10/16 C: 9/15 15 0 y AF,TT, CRP N RT Injection Shuxuening injection 20 ml+ 0.9%
NaCI 250 ml, iv, qd+ RT
Li 2009 [43] 68(36/32) 49~64 T:16/20 C:14/18 30 0 y ECG, blood lipid,
ET-1,No,
Y RT Chinese patent
drug
Tongxinluo capsule, 2.14 g, tid +
RT
Feng 2005 [44] 32(16/16) 37~51 T:7/9 C:8/8 28 0 y AF,TT ET-1 U RT Chinese patent
drug
Tongxinluo capsule, 1.14 g tid+ RT
Table Legends :
* Studies were marked by the surname of the first author followed by the year of publication . An abbreviation of the first name was appended if authors share the same surname.
Abbreviation: Co(d)-medication course; F-follow-up; C-compatibility; Y-yes; U-unclear; N-no; RT-routine treatment; A-the symptom of angina; AF-angina frequency; TT-treadmill test; ECG-electrocardiogram; AE-adverse
event; CI-intervention in the controlled group; TI- intervention in the treatment group; T- treatment group;
C-controlled group, d-day; m-month.
Herbal supplements in the decoction:
1 Nourishing Qi and Blood Decoction (huangqi 30 g, chaihu 12 g, gualoupi 15 g, xiebai 15 g, houpou 15 g, jiangbanxia 9 g, zhiqiao 9 g, huanglian 3 g, tanxiang 9 g, dansen 9 g, chuanxiong 9 g, danggui 6 g, baishao
12 g, baizhu 15 g, zhigancao 6 g, dangshen 12 g).
2 Xiaoyao decoction (chaihu 10 g, danggui 15 g, chishao15g, baishao 15 g, gancao 6 g, danshen 30 g, chuanxiong 10 g, honghua 10 g, sanqi 3 g, qianhu 10 g).
3 Wenxin granules (dangshen, huangjing, sanqi, hupo, gansong).
4 Kuanxionghuoxue decoction(chaihu 10 g, zhiqiao 12 g, guoloupi 15 g, xiebai 10 g, fuling 12 g, baizhu 12 g, chenpi12g, chuanxiong 10 g, danggui 12 g, danshen 15 g, yanhusuo 15 g, honghua 15 g).
5 Taohongsiwu decoction (taoren 10 g, honghua 10 g, danggui 15 g,danshen 30 g, sanqi powder 3 g, guoloupi 18 g, gegen 30 g, chuanxiong 10 g, guizhi 6 g).
6 Xuefuzhuyu decoction(danggui 15 g, taoren 15 g, honghua 15 g, chishao 15 g, chuanxiong 15 g, shengdihuang 15 g, niuxi 10 g, zhiqiao 10 g, chaihu 10 g, jiegeng 6 g).
7 Guanmailing formula(danshen 20 g, tanxiang 10 g, sharen 10 g, gualou 10 g, xiebai 10 g, zhiqiao 10 g, sanqi 10 g, chuanxiong 10 g, yinxingye 10 g, honghua 6 g, jiuxiangchong 10 g, 150 ml one pocket).
8 Guanmaiding (huangqi, sanleng, xiebai).
9 Individualized Chinese herbal formula against different patterns of syndrome.
Basic formula: chaihu, zhiqiao, chishao, baishao, xiangfu, chuanxiong, fuling, chenpi, suanzaoren, danshen, yuanzhi, taoren, honghua, danggui and gancao.

























Table 2 Assessment of the methodological quality for individual trials
Studies year* Randomization Allocation concealment Blinding Loss to follow-up ITT analysis
Sun 2007 [24] yes unclear unclear no unclear
Ge 2011 [25] yes unclear unclear no unclear
Peng 2011 [26] yes unclear yes no unclear
Niu 2008 [27] yes unclear yes no unclear
Gao 2005 [28] yes unclear unclear no unclear
Xu 2011 [29] yes unclear unclear no unclear
Bi 2003 [30] yes unclear unclear no unclear
Wang 2009 [31] yes unclear unclear no unclear
Xu LJ 2002 [32] yes unclear unclear no unclear
Liu 2008 [33] yes unclear unclear no unclear
Zhang 2002 [34] yes unclear unclear no unclear
Lu 2007 [35] yes unclear unclear no unclear
Zhu 2003 [36] yes unclear unclear no unclear
Liang 2005 [37] yes unclear unclear no unclear
Yuan 2008[38] yes unclear unclear no unclear
Wang GF 2008 [39] yes unclear unclear no unclear
Zhang SL 2008 [40] yes unclear unclear no unclear
Zhang XY 2008 [41] yes unclear unclear no unclear
Wu 2010 [42] yes unclear unclear no unclear
Li 2009 [43] yes unclear unclear no unclear
Feng 2005 [44] yes unclear unclear no unclear
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search on CSX.
Methods
This systematic review is conducted according to the Pre-
ferred Reporting Items for Systematic Reviews and Meta-
analyses: Additional file 1: The PRISMA Statement.
Ethics
Data for this study was acquired through previously pub-
lished work, no patient or hospital data was accessed.Figure 2 Angina improvement.Therefore, written consent and institutional ethical review
was not required for this research.
Search strategy
We systematically searched for studies on CSX published
in either Chinese or English. The databases that were
searched included the Cochrane Central Register of Con-
trolled Trials (Issue 3, 2011), PubMed (1978–2011.9),
EMBASE (1995–2011), MEDLINE (1984–2010.5), CINAL
(1984–2010.5), CNKI (1980–2011), CBM disc (1981–
2011.9), WANFANF (1980–2011.9), and VIP (1989–
Figure 3 Angina frequency.
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terms in combination with free words. Details of the
search strategy for the English databases are as follows:
1. Angina, Microvascular
2. Cardiac Syndrome X
3. X Syndrome, Angina
4. Angina X Syndrome
5. Angina X Syndromes
6. Syndrome, Angina X
7. Syndrome X, Cardiac
8. Angina Pectoris with Normal Coronary Arteriogram
9. Syndrome X, Angina
10. Angina Syndrome X
11. Angina Syndrome Xs
12. Syndrome Xs, Angina
13. Chinese medicine [All Fields]
14. (1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or
11 or 12) [Title/Abstract]
15. 13 AND 14
Details of the search strategy for the Chinese databases
are as follows:Figure 4 Exercise duration outcome in treadmill test.The Chinese characters used to perform the search are
hereafter stated in Chinese pinyin
For example:
(Zhuti (title/abstract) = xinzangXzonghezheng (cardiac
syndrome X) or weixueguanxingxinjiaotong (microvas-
culature)
We also checked the references of literature for pos-
sible identification of relevant studies. Electronically in-
accessible journal articles were manually retrieved.
Inclusion criteria
 The study is a randomized controlled trial (RCT).
 The study includes participants diagnosed with CSX
by the criteria listed in ANGINA PECTORIS AND
NORMAL CORONARY ARTERIES: CARDIAC
SYNDROME X [18].
 The study includes intervention and comparison of
any of the following:
A. TCM + routine treatment* vs. routine treatment
B. TCM + routine treatment vs. routine treatment +placebo.
C. TCM vs. routine treatment
Figure 5 ET-1 (ng/L).
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beta-blockers, angiotensin-converting enzyme
inhibitors, angiotensin receptor blockers, and
calcium channel blockers, as recommended in the
essay Therapeutic Options for the Management of
Patients with Cardiac Syndrome X [19].
 Outcomes to be measured include symptom
improvement and electrocardiograph (ECG) changes
and/or treadmill test results. Any adverse event
defined in “ICH—GCP 1997” [20] should be recorded.
Exclusion criteria
We excluded studies with unclear diagnostic criteria and
without full texts or the use of other TCM therapeutic
methods except herbs. Intervention for the treatment
group was limited to Chinese herbs. Combinations of
herbs and other forms of treatment (e.g., acupuncture or
moxibustion) were excluded.
Study selection
Two researchers (W.J.Y. and X.L.) independently under-
took the aforementioned search and managed the search
results using Note Express 2 software. Ineligible studies
were excluded after reading the title and abstract, and theFigure 6 Angina Improvement in Group B.full texts of the remaining studies were scanned for con-
firmation. When disagreement arose between the two re-
searchers, they sought help from a third reviewer (S.H.C.).
Data collection
Both researchers (W.J.Y. and X.L.) independently ex-
tracted data from all included studies and input them into
two Excel sheets. One sheet contained the general infor-
mation of the studies, including the authors’ names (the
first author was listed if there was more than one), pub-
lication date, sample size, age of participants, gender,
interventions and comparisons, treatment courses, and
outcomes. The other sheet included items for quality as-
sessment listed in the Cochrane risk of bias tool [21]. The
above information was then carefully checked by two
other researchers (C.J. and Z.S.). Any disagreement was
resolved through discussion, and errors were corrected.
Statistical analysis
The two researchers (W.J.Y. and X.L.) used Review
Manager 5.0.2, provided by the Cochrane corporative
network, to analyze the data. Effect measures were
presented using odds ratios (OR) for dichotomous data
and weighted mean differences (WMD) or standardized
Figure 7 ECG improvement in Group B.
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95% confidence intervals (CI). The chi-square test was
used to test heterogeneity across studies [22] with a sig-
nificance level of 0.05. Data were analyzed with a fixed-
effect model if no statistical heterogeneity was observed
(P > 0.05 or I2 < 50%). In the presence of heterogeneity,
the two researchers (W.J.Y. and X.L.) checked the data
entered and explored the variation by conducting sub-
group analysis. If the variation could not be explained, we
performed a random-effects meta-analysis and interpreted
the effect measure with care. A funnel plot was formed to
detect publication bias [23].Subgroup analysis, sensitivity, and meta-regression
Subgroup analysis was conducted to show the magnitudes
of the effects in different subgroups and determine
whether there was a different effect of an intervention in
different situations. Meta-regression analysis was con-
ducted to identify possible causes for differences across the
groups.Results
A total of 903 studies (900 in Chinese and 3 in English)
were identified through electronic searches; 101 of them
were included for further assessment after both re-
searchers examined the title and abstract of all studies and
excluded duplicates, animal experiments, reviews, and
others. We read the full texts of all 101 articles and dis-
covered and excluded other ineligible studies. The finalTable 3 Meta-regression of basic characteristics of RCTs and O
logRR Coef. Std. Err.
Publication year −0.0362491 −0.53
Sample size 0.0006184 0.09
Medication course 0.0027627 0.25
Type of intervention 0.12211139 0.60
_cons 72.78822 0.52result included 21 articles [24-44], all in Chinese (see
Figure 1).
General characteristics of the included studies
All 21 RCTs, which involved 1143 patients aged 35 to
76 years, were published between 2002 and 2011. In all
studies excluding two (Liu 2008 and Zhu 2003), female
participants outnumbered male participants. Treatment
courses ranged from 7 days to 1 year. In one study
(Xv 2002), the duration was 7 days, and in another study
(Wang 2009), it was 14 days. The treatment length was
15 days in three studies34,36,42 and 28 days in nine stud-
ies. The longest treatment length (Lu 2007) was 84 days.
The other two studies (Liu 2008 and Zhu 2003) did not
report the medication treatment course. Only two stud-
ies (Bi 2003 and Xv 2002) reported follow-up data.
Of the 21 RCTs, 12 compared TCM plus routine treat-
ment with routine treatment alone, eight compared TCM
with routine treatment, and the remaining RCT (Liang
2005) compared TCM combined with routine treatment
versus placebo, which were combined with routine treat-
ment. TCM interventions included Chinese patented
drugs (12 studies), decoction (seven studies), and injection
(two studies). With regard to outcome measures, angina
improvement was reported in 15 studies, angina frequency
in nine studies, and treadmill test results in 11 studies.
Eight trials used ECG improvement as the primary out-
come measure, two trials used TCM syndrome improve-
ment, and seven used changes in cytokine levels such as
endostatin ET-1 or C-reactive protein (CRP). Only oneRs of angina improvement
t p [95% Conf. Interval]
0.0690226 0.627 -.2278864 0.1553883
0.0072663 0.936 −0.019556 0.0207929
0.0108927 0.812 −0.0274803 0.0330058
0.2020443 0.578 −0.4388511 0.683079
138.6524 0.627 −312.1727 457.7491
Table 4 Meta-regressions of basic characteristics of RCTs and mean difference of angina frequency
Mean difference Coef. Std.err T P [95% Conf. Interval]
Publication year 8.70691 19.39486 0.45 0.697 −74.74244 92.15626
Sample size .3612435 3.40234 0.11 0.925 −14.27784 15.00033
Medication course .3836948 2.185376 0.18 0.877 −9.019221 9.786611
Type of interventions 67.53072 71.69857 0.94 0.446 −240.9633 376.0248
_cons −17557.2 39125.53 −0.45 0.698 −185900.8 150786.4
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reported safety outcomes (see Table 1).
Quality assessment of the included studies
All 21 articles mentioned the word “randomization,” but
only two studies (Sun 2007 and Bi 2003) elaborated on
the randomization method (random number table). Only
two studies (Peng 2011 and Niu 2008) mentioned the
performance of single blinding. None mentioned alloca-
tion concealment or intention-to-treat analysis (see
Table 2).
Efficacy and safety analysis
The 21 RCTs were divided into two subgroups for fur-
ther analysis with consideration of clinical heterogeneity
across the studies. Group A (13 studies) compared TCM
plus routine treatment with routine treatment alone,
while Group B (eight studies) evaluated the effects of
TCM relative to routine treatment. One study that com-
pared the effects of TCM plus routine treatment with
that of placebo plus routine treatment was assigned to
Group A. Descriptions and interpretations of angina and
ECG improvement for patients in all studies followed
the rules prescribed in the Efficacy Criteria for Angina of
Coronary Heart Disease [45]. TCM syndromes were de-
termined against the same criteria: Guideline for Clinical
Research of Chinese Medicine (New Drug) [46].
Subgroup analysis
Group A: TCM + RT vs. RT
Nine studies involving 239 participants in the treatment
group reported angina improvement. No statistical hetero-
geneity was found among these studies (P = 0.13 > 0.05,
I2 = 36%) (see Figure 2). The results showed that TCM
combined with routine treatment was more effective than
routine treatment alone (OR = 1.34, 95% CI = 1.2–1.50).Table 5 Meta-regressions of basic characteristics of RCTs and
Mean difference Coef. t
Publication year 0.1781444 0.4136524
Sample size 0.0122943 0.1209633
Medication course −0.0931837 0.0898212
Type of interventions −4.132576 2.23568
_cons −352.001 831.7356Eight studies reported the patients’ angina frequency per
week. A random-effect model was applied because obvi-
ous heterogeneity was observed among these studies, as
seen in Figure 3 (P < 0.00001, I2 = 94%). The results indi-
cated that patients in the treatment group experienced an-
gina almost five times less frequently than those in the
control group (WMD = −4.91, 95% CI = −6.56 to −3.25).
Nine studies reported outcomes of the Bruce Protocol
Treadmill Test. Either exercise duration or the time to
1-mm ST segment depression was recorded. Exercise dur-
ation (measured in seconds) is known to be a health pre-
dictor for patients with coronary heart disease [47] and
was reported in seven of the nine studies (excluding Wu
2010 and Li 2009). A random-effect model was applied
because obvious heterogeneity was observed (P < 0.0001,
I2 = 79%) (see Figure 4). Patients in the TCM plus routine
treatment group had a nearly 1-min improvement in exer-
cise duration (WMD = 77.31, 95% CI = 39.70–114.93).
Five studies reported changes in ET-1 levels. As seen in
Figure 5, statistical heterogeneity was observed and the
units of outcomes varied; thus, a random-effect model
was used (P = 0.002, P < 0.05, and I2 = 77%). Pooled re-
sults indicated greater effects of TCM combined with rou-
tine medicine in decreasing ET-1 levels (SMD = −1.12,
95% CI = −1.73 to −0.50).
Spearman correlation analysis using SAS9.1 software
showed no correlation between angina improvement and
reduced angina frequency or between angina improve-
ment and changes in ET-1 levels.
Group B: TCM vs. RT
The forest plots in Figures 6 and 7 show no signifi-
cant heterogeneity across studies (P = 0.55, I2 = 0% and
P = 0.06, I2 = 60%, respectively). The pooled results
showed OR = 1.45 (95% CI = 1.26–1.66) for angina im-
provement and OR = 1.24 (95% CI = 1.09–1.40) for
ECG tests.mean difference of Treadmill Test results
Std. Err. P>t [95% Conf. Interval]
0.43 0.696 −1.138282 1.494571
0.10 0.925 −0.3726648 0.3972535
−1.04 0.376 −0.3790348 0.1926673
−1.85 0.162 −11.24751 2.982355
−0.42 0.701 −2998.955 2294.953
Figure 8 Funnel plot of angina improvement in Group A.
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No statistical heterogeneity is observed in Figures 2, 6,
or 7. However, clinical heterogeneity across trials still
needs special attention. The final effect sizes were
influenced by multiple factors such as sample size, medi-
cation course, publication year, and even different forms
of Chinese medicine. As seen in Figures 3 and 4, meta-
regression was conducted to test the reliability of the
pooled analysis and search for possible causes for this het-
erogeneity. We conducted meta-regression by residual
maximum likelihood (REML) with Knapp-Hartung modi-
fication. Tau2 was equal to 0.02809 in Table 3, 6.82 in
Table 4, and 1700 in Table 5 as REML estimates of
between-study variance. I2 was 0.02809%, 91.27%, and
61.44% in terms of the proportion of residual variation
due to heterogeneity. The adjusted R2 value was equalFigure 9 Funnel plot of angina improvement in Group B.to −684.96%, 15.63%, and 0.65%, with the proportion of
between-study variance explained. Data in Tables 3, 4, and
5 suggest that these four clinical aspects of heterogeneity
had no statistically significant effect on the final results.
However, only four studies used an identical form and
dosage of TCM intervention (Tongxinluo capsules), which
shows that clinical heterogeneity existed and that its influ-
ence cannot be ruled out. According to statistical tests,
the results shown in Figure 2 are more likely to reflect the
real effects of TCM. Interpretation of the results in
Figures 3 and 4 is controversial.
Safety analysis and publication bias
Ten of the 21 RCTs reported routine blood or urine
examination results as well as liver and kidney function
test results. No side effects were reported with the
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of stomachache in the treatment group. Funnel plot ana-




The results of this study suggest that women are more
likely to suffer from CSX based on the fact that patients
were randomly recruited.
Improving patient outcomes is the primary goal of CSX
management. Compared with routine Western medicine,
TCM has the potential of being more effective in relieving
symptoms, improving ECG results, and prolonging exer-
cise duration in treadmill tests; however, these advantages
were not obvious based on the evidence collected so far.
The results in Groups A and B show that Chinese medi-
cine with or without routine Western medicine could im-
prove the degree of angina and reduce the frequency of
angina attacks by five times per week. Besides these pre-
senting symptoms of the patients, objective measurements
such as ECG and treadmill testing also provided evidence.
Because CSX and coronary heart disease share the same
symptom of chest pain, the effective solution for the treat-
ment of CSX may provide useful information in terms of
symptom improvement for coronary heart disease. Studies
in this field will be meaningful.
One mechanism of action of the Chinese herbal medi-
cines prescribed to patients with CSX is believed to in-
volve regulation of endothelial function. A number of cell
factors, including ET-1, ET-21, CRP, hs-CRP, and ET-1,
were measured and recorded in most of the involved stud-
ies. In addition, a comprehensive study (by one researcher,
C.J.) of the pharmacological actions of all 48 types of herbs
involved in TCM showed that these herbs can improve or
protect endothelial function. Analysis of the forest plot
also provided hints regarding this hypothesis. However,
the undetected association between ET-1 levels and an-
gina improvement in this study may have been caused by
the small size of the studies.
Furthermore, we identified a total of 259 case reports
and case series from our search, almost 12 times the num-
ber of RCTs conducted on this topic. Observational stud-
ies have been published since the early 1990s, whereas the
first RCT was carried out in 2002. This shows TCM re-
searchers’ growing interest in CSX studies and the difficul-
ties they faced in conducting high-quality RCTs. However,
observational studies might also be valuable resources for
further research.
Finally, it should be pointed out that the outcomes
reported in the included studies in this review were all
short-term outcomes, such as symptom relief before and
after treatment. The long-term effects of TCM on patients
with CSX and its role in the prognosis were scarcelydiscussed. This may provide a starting point for future
studies.
Limitations
This research only included articles published in English
and Chinese. Studies published in other languages were
not considered. The sample sizes of the present studies
were small, which may lead to bias. The 21 trials included
in this review were of moderate to low quality. As a result,
the evidence generated needs to be interpreted with
caution.
Implications for further study
These clinical trials show that the basic mechanism of
Chinese herbs in relieving chest pain mainly involves
endothelial function and the ET-1 pathway. This should
draw our attention because Chinese herbs may be helpful
for developing and optimal for the treatment of CSX or
even coronary heart disease. The methodology of RCTs
should be modified in terms of double blinding and allo-
cation concealment. Female patients suffering from CSX
should receive more attention.
Conclusion
This review is the first to systematically evaluate the ef-
fects of TCM in the treatment of CSX, addressing the
lack of this type of research. In conclusion, TCM shows
potential in treating CSX, but its efficacy seems to be
minor thus far. Rigorous and multicenter, large-scale
clinical trials must be carried out to reveal the exact ef-
fectiveness of TCM.
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